A Controlled Study of a Group Mindfulness Intervention for Individuals Living With Inflammatory Bowel Disease.

Abstract:

BACKGROUND:This study aimed to evaluate the feasibility, acceptability, and effectiveness of a mindfulness-based intervention for patients with inflammatory bowel disease (MI-IBD). DESIGN:Treatment-as-usual control versus mindfulness-based stress reduction intervention. METHODS:Sixty patients participated in either the MI-IBD (n = 33) or treatment-as-usual group (n = 27) conditions. The MI-IBD consisted of an 8-week mindfulness-based stress reduction training group. Outcome measures were administered at baseline (before intervention), immediately after intervention, and 6 months after intervention. Primary outcomes included measures of quality of life, psychological distress (depression and anxiety), and mindfulness. Data for MI-IBD group participants also included weekly attendance, daily minutes meditated, and satisfaction with the program. RESULTS:There were no baseline differences between intervention and control groups on demographic variables or inflammatory bowel disease severity. Compared with the control group, the MI-IBD group reported significantly greater improvements in anxiety, quality of life, and mindfulness at after intervention, with reduction in depression and improvements in quality of life and mindfulness maintained at 6 months after intervention. CONCLUSIONS:Results demonstrate the feasibility, acceptability, and efficacy of a mindfulness intervention for patients with inflammatory bowel disease, with medium-to-large effects on psychological distress, quality of life, and mindfulness.

journal_name

Inflamm Bowel Dis

authors

Neilson K,Ftanou M,Monshat K,Salzberg M,Bell S,Kamm MA,Connell W,Knowles SR,Sevar K,Mancuso SG,Castle D

doi

10.1097/MIB.0000000000000629

subject

Has Abstract

pub_date

2016-03-01 00:00:00

pages

694-701

issue

3

eissn

1078-0998

issn

1536-4844

journal_volume

22

pub_type

杂志文章
  • Smoking cessation alters intestinal microbiota: insights from quantitative investigations on human fecal samples using FISH.

    abstract:BACKGROUND:There has been a dramatic increase in investigations on the potential mechanistic role of the intestinal microbiota in various diseases and factors modulating intestinal microbial composition. We recently reported on intestinal microbial shifts after smoking cessation in humans. In this study, we aimed to co...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000129

    authors: Biedermann L,Brülisauer K,Zeitz J,Frei P,Scharl M,Vavricka SR,Fried M,Loessner MJ,Rogler G,Schuppler M

    更新日期:2014-09-01 00:00:00

  • miR-29a-5p/STAT3 Positive Feedback Loop Regulates TETs in Colitis-Associated Colorectal Cancer.

    abstract:BACKGROUND:Interleukin (IL)-6/signal transducers and activators of transcription 3 (STAT3) signaling plays an important role in the development of colitis-associated colorectal cancer (CAC). The mechanism of CAC formation remains unclear, and the relationship between miRNAs and the IL-6/STAT3 signaling pathway in the d...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz281

    authors: Wang A,Deng S,Chen X,Yu C,Du Q,Wu Y,Chen G,Hu L,Hu C,Li Y

    更新日期:2020-03-04 00:00:00

  • Two-stage genome-wide methylation profiling in childhood-onset Crohn's Disease implicates epigenetic alterations at the VMP1/MIR21 and HLA loci.

    abstract:BACKGROUND:As a result of technological and analytical advances, genome-wide characterization of key epigenetic alterations is now feasible in complex diseases. We hypothesized that this may provide important insights into gene-environmental interactions in Crohn's disease (CD) and is especially pertinent to early onse...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000179

    authors: Adams AT,Kennedy NA,Hansen R,Ventham NT,OʼLeary KR,Drummond HE,Noble CL,El-Omar E,Russell RK,Wilson DC,Nimmo ER,Hold GL,Satsangi J

    更新日期:2014-10-01 00:00:00

  • Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine.

    abstract::Diagnostics of inflammatory bowel diseases (IBDs) currently relies on a combination of biological and morphological tests. The current method of diagnostic remains a critical challenge for physicians in part due to their invasiveness and also for their limitations in term of diagnosis, prognosis, disease activity and ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0000000000000444

    authors: Viennois E,Zhao Y,Merlin D

    更新日期:2015-10-01 00:00:00

  • Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease.

    abstract:BACKGROUND:Adverse drug reactions to azathioprine, the prodrug of 6-mercaptopurine, occur in 15%-38% of patients and the majority are not explained by thiopurine-S-methyltransferase (TPMT) deficiency. Azathioprine is known to induce glutathione depletion and consumption of glutathione is greater in cells with high glut...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20004

    authors: Stocco G,Martelossi S,Barabino A,Decorti G,Bartoli F,Montico M,Gotti A,Ventura A

    更新日期:2007-01-01 00:00:00

  • Homing imprinting and immunomodulation in the gut: role of dendritic cells and retinoids.

    abstract::Lymphocyte migration is at the heart of chronic inflammatory ailments, including inflammatory bowel disease (IBD). Whereas naïve lymphocytes migrate to all secondary lymphoid organs, they are mostly excluded from nonlymphoid peripheral tissues. Upon activation, lymphocytes change their pattern of adhesion receptors an...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.20280

    authors: Mora JR

    更新日期:2008-02-01 00:00:00

  • Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics.

    abstract:BACKGROUND:Data from CHARM, a 56-week, randomized controlled trial of adalimumab for patients with moderately to severely active Crohn's disease (CD), were used to evaluate outcomes of adalimumab dosage adjustment. METHODS:Patients randomized to blinded adalimumab 40 mg every other week (EOW) in CHARM were the focus o...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/ibd.21328

    authors: Sandborn WJ,Colombel JF,Schreiber S,Plevy SE,Pollack PF,Robinson AM,Chao J,Mulani P

    更新日期:2011-01-01 00:00:00

  • Enhanced formation of advanced oxidation protein products in IBD.

    abstract:BACKGROUND:Advanced oxidation protein products (AOPPs) are new protein markers of oxidative stress with pro-inflammatory properties, accumulated in many pathological conditions. The issue of their enhanced formation in IBD has not been addressed yet. METHODS:The concentration of relative AOPPs (rAOPP; concentration of...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20383

    authors: Krzystek-Korpacka M,Neubauer K,Berdowska I,Boehm D,Zielinski B,Petryszyn P,Terlecki G,Paradowski L,Gamian A

    更新日期:2008-06-01 00:00:00

  • Are endoscopic endpoints reliable in therapeutic trials of ulcerative colitis?

    abstract:BACKGROUND:The consistency of endoscopic and histologic findings in patients with ulcerative colitis (UC) has not been elucidated. Choice of assessment may affect study outcomes. METHODS:Post hoc analyses were performed using data from 2 randomized, controlled multicenter trials: (1) SAG-26, mesalazine granules for in...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.MIB.0000437044.43961.00

    authors: Wolff S,Terheggen G,Mueller R,Greinwald R,Franklin J,Kruis W

    更新日期:2013-11-01 00:00:00

  • IBD Systems Biology Is Here to Stay.

    abstract:BACKGROUND:Systems biology is a rapidly advancing field of science that allows us to look into disease mechanisms, patient diagnosis and stratification, and drug development in a completely new light. It is based on the utilization of unbiased computational systems free of the traditional experimental approaches based ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izaa343

    authors: Fiocchi C,Iliopoulos D

    更新日期:2021-01-13 00:00:00

  • Human β-defensin 3 peptide is increased and redistributed in Crohn's ileitis.

    abstract:BACKGROUND:Antimicrobial peptides (AMPs) maintain a sterile environment in intestinal crypts, limiting microbial colonization and invasion. Decreased AMP expression is proposed to increase the risk for inflammatory bowel disease. Expression and function of inducible AMPs, human β-defensin 2 and 3 (hBD-2 and hBD-3), rem...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0b013e318280b11a

    authors: Meisch JP,Nishimura M,Vogel RM,Sung HC,Bednarchik BA,Ghosh SK,Fu P,McCormick T,Weinberg A,Levine AD

    更新日期:2013-04-01 00:00:00

  • Hospital Admissions, Biological Therapy, and Surgery in Familial and Sporadic Cases of Inflammatory Bowel Disease: A Population-Based Cohort Study 1977-2011.

    abstract:BACKGROUND:Easily accessible predictors of disease course in inflammatory bowel disease (IBD) are scarce, and it remains largely unknown whether a family history of IBD predicts the course of Crohn's disease (CD) and ulcerative colitis (UC). We aimed to compare the course of disease in familial and sporadic cases of IB...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000545

    authors: Trier Moller F,Andersen V,Andersson M,Jess T

    更新日期:2015-12-01 00:00:00

  • Molecular Signaling and Dysfunction of the Human Reactive Enteric Glial Cell Phenotype: Implications for GI Infection, IBD, POI, Neurological, Motility, and GI Disorders.

    abstract:BACKGROUND:Clinical observations or animal studies implicate enteric glial cells in motility disorders, irritable bowel syndrome, inflammatory bowel disease, gastrointestinal (GI) infections, postoperative ileus, and slow transit constipation. Mechanisms underlying glial responses to inflammation in human GI tract are ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000854

    authors: Liñán-Rico A,Turco F,Ochoa-Cortes F,Harzman A,Needleman BJ,Arsenescu R,Abdel-Rasoul M,Fadda P,Grants I,Whitaker E,Cuomo R,Christofi FL

    更新日期:2016-08-01 00:00:00

  • Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.

    abstract:BACKGROUND:Infliximab is an effective therapy for inflammatory bowel disease (IBD). However, more than 50% of patients lose response. Empiric dose intensification is not effective for all patients because not all patients have objective disease activity or subtherapeutic drug level. The aim was to determine how an obje...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000376

    authors: Huang VW,Prosser C,Kroeker KI,Wang H,Shalapay C,Dhami N,Fedorak DK,Halloran B,Dieleman LA,Goodman KJ,Fedorak RN

    更新日期:2015-06-01 00:00:00

  • Eosinophils and IL-33 Perpetuate Chronic Inflammation and Fibrosis in a Pediatric Population with Stricturing Crohn's Ileitis.

    abstract:BACKGROUND:Fibrostenosis and stricture are well-recognized endpoints in Crohn's disease (CD). We hypothesized that stricturing CD is characterized by eosinophilia and epithelial IL-33. We proposed that eosinophil exposure to IL-33 would perpetuate inflammatory chronicity and subsequent fibrostenosis. METHODS:We perfor...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000512

    authors: Masterson JC,Capocelli KE,Hosford L,Biette K,McNamee EN,de Zoeten EF,Harris R,Fernando SD,Jedlicka P,Protheroe C,Lee JJ,Furuta GT

    更新日期:2015-10-01 00:00:00

  • Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse.

    abstract:BACKGROUND:We assessed whether selective granulocyte and monocyte/macrophage adsorption apheresis maintained clinical remission in asymptomatic inflammatory bowel disease (IBD) patients at significant risk of clinical relapse. METHODS:Sixty asymptomatic patients (age 18-70 years) with IBD (in clinical remission) with ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/ibd.20505

    authors: Maiden L,Takeuchi K,Baur R,Bjarnason I,O'Donohue J,Forgacs I,Chung-Faye G,Sanderson J,Bjarnason I

    更新日期:2008-10-01 00:00:00

  • Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease.

    abstract:BACKGROUND:Crohn's disease (CD)-associated dysbiosis could predispose patients to relapse. Gut microbiota composition of patients from the prospective cohort study designed to identify predictive factors of clinical relapse after infliximab discontinuation (STORI Study) was investigated to determine the impact of dysbi...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/MIB.0000000000000036

    authors: Rajca S,Grondin V,Louis E,Vernier-Massouille G,Grimaud JC,Bouhnik Y,Laharie D,Dupas JL,Pillant H,Picon L,Veyrac M,Flamant M,Savoye G,Jian R,Devos M,Paintaud G,Piver E,Allez M,Mary JY,Sokol H,Colombel JF,Seksik P

    更新日期:2014-06-01 00:00:00

  • Immune System Activation in C3H/HeJBir Mice Exhibiting Spontaneous Perianal Ulceration.

    abstract::: We report our initial characterization of the immune system in C3H/HeJBir mice that spontaneously develop perianal ulceration. Analysis of lymphokine production by mucosal and systemic lymphoid cells obtained from these mice revealed higher levels of interleukin (IL)4 in supernatants of in vitro stimulated Peyer's p...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:

    authors: Tonkonogy SL,Sartor BR

    更新日期:1997-04-01 00:00:00

  • Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis.

    abstract:BACKGROUND:Guidelines mandate screening for latent tuberculosis infection (LTBI) prior to anti-tumor necrosis factor (anti-TNF) therapy in patients with inflammatory bowel disease (IBD). However, many are already on immunosuppressive therapy (IST) that may affect the precision of the Tuberculin skin test (TST). Our aim...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,meta分析

    doi:10.1002/ibd.22901

    authors: Shahidi N,Fu YT,Qian H,Bressler B

    更新日期:2012-11-01 00:00:00

  • Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile: antibiotics alone or combined antibiotics/immunomodulators?

    abstract:BACKGROUND:The optimal management of Clostridium difficile infection (CDI) in flaring inflammatory bowel disease (IBD) patients has not been defined. Limited data suggest that coadministration of immunomodulators (IM) with antibiotics (AB) results in a worse outcome. We investigated the prevalent practice among North A...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21514

    authors: Yanai H,Nguyen GC,Yun L,Lebwohl O,Navaneethan U,Stone CD,Ghazi L,Moayyedi P,Brooks J,Bernstein CN,Ben-Horin S

    更新日期:2011-07-01 00:00:00

  • Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease.

    abstract:BACKGROUND:The Crohn's Disease Activity Index (CDAI) has been criticized for being weakly correlated with bowel inflammation. We assessed correlation between Simple Endoscopic Score for Crohn's Disease (SES-CD) and individual CDAI items stratified by disease location to better understand this relationship. METHODS:We ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz241

    authors: Lewis JD,Rutgeerts P,Feagan BG,D'haens G,Danese S,Colombel JF,Reinisch W,Rubin DT,Selinger C,Bewtra M,Barcomb L,Lacerda AP,Wallace K,Butler JW,Wu M,Zhou Q,Liao X,Sandborn WJ

    更新日期:2020-01-06 00:00:00

  • Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.

    abstract:BACKGROUND:Clostridium difficile infection (CDI) is common in patients with inflammatory bowel disease (IBD), often leading to diagnostic confusion and delays in IBD therapy escalation. This study sought to assess outcomes after CDI in IBD patients exposed to new or escalated immunosuppressive therapy. METHODS:This mu...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1093/ibd/izy308

    authors: Lukin DJ,Lawlor G,Hudesman DP,Durbin L,Axelrad JE,Passi M,Cavaliere K,Coburn E,Loftus M,Jen H,Feathers A,Rosen MH,Malter LB,Swaminath A,IBD-ReMEdY Study (Research, Mentoring, Education New York).

    更新日期:2019-03-14 00:00:00

  • Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity.

    abstract:Background:The Crohn's Disease Activity Index (CDAI), a scoring index including patient-reported outcomes (PROs), has known limitations for measuring intestinal inflammatory disease burden. Noninvasive markers of inflammation could prove more accurate than PROs; thus, regulatory authorities are exploring the use of PRO...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1093/ibd/izx018

    authors: Morris MW,Stewart SA,Heisler C,Sandborn WJ,Loftus EV,Zello GA,Fowler SA,Jones JL

    更新日期:2018-01-18 00:00:00

  • Predictors of fibrostenotic Crohn's disease.

    abstract::Intestinal fibrosis is a common and serious complication of Crohn's disease (CD) and as it can occur at any time during the disease course, it is crucial to identify patients at risk. The aim is not only to understand the pathophysiology of fibrogenesis but to be able to accurately inform subjects about their disease ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.21627

    authors: Rieder F,Lawrance IC,Leite A,Sans M

    更新日期:2011-09-01 00:00:00

  • Defect in CEACAM family member expression in Crohn's disease IECs is regulated by the transcription factor SOX9.

    abstract:BACKGROUND:CEACAM1, CEACAM5, and CEACAM6 represent 3 of the CEACAM (carcinoembryonic antigen-related cell adhesion molecule) subfamily members expressed on intestinal epithelial cells (IECs). Deficiency in their expression, as seen in inflammatory bowel disease (IBD), results in the lack of activation of CD8+ regulator...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21023

    authors: Roda G,Dahan S,Mezzanotte L,Caponi A,Roth-Walter F,Pinn D,Mayer L

    更新日期:2009-12-01 00:00:00

  • Quality and publication success of abstracts of randomized clinical trials in inflammatory bowel disease presented at Digestive Disease Week.

    abstract:BACKGROUND:The incorporation of abstracts from scientific meetings into systematic reviews and practice guidelines may reduce publication bias and delays in implementing therapeutic interventions. METHODS:All abstracts of Phase III randomized controlled trials in inflammatory bowel disease accepted at Digestive Diseas...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21131

    authors: Kottachchi D,Nguyen GC

    更新日期:2010-06-01 00:00:00

  • The Management of Intestinal Penetrating Crohn's Disease.

    abstract::Crohn's disease (CD) leads to the development of complications through progressive uncontrolled inflammation and the transmural involvement of the bowel wall. Most of the available literature on penetrating CD focuses on the perianal phenotype. The management of nonperianal penetrating complications poses its own set ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1093/ibd/izx108

    authors: Hirten RP,Shah S,Sachar DB,Colombel JF

    更新日期:2018-03-19 00:00:00

  • AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, which is currently treated with injected monoclonal antibodies specific for tumor necrosis factor (TNF). We developed and characterized AVX-470, a novel polyclonal antibody specific for human TNF. We evaluated t...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0b013e3182a11958

    authors: Bhol KC,Tracey DE,Lemos BR,Lyng GD,Erlich EC,Keane DM,Quesenberry MS,Holdorf AD,Schlehuber LD,Clark SA,Fox BS

    更新日期:2013-10-01 00:00:00

  • Clinical epidemiology of Crohn's disease in Arabs based on the Montreal Classification.

    abstract:BACKGROUND:There has been a remarkable increase in the incidence of Crohn's disease (CD) among Arabs in recent years. We conducted this study to determine the clinical epidemiology of CD in Kuwait. METHODS:Sociodemographic and clinical information was collected for a continuous series of 206 Arab patients with CD and ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21890

    authors: Siddique I,Alazmi W,Al-Ali J,Al-Fadli A,Alateeqi N,Memon A,Hasan F

    更新日期:2012-09-01 00:00:00

  • Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms.

    abstract::Crohn's disease is associated with an excessive T helper (TH) type 1 inflammatory immune response. Reducing the influx of disease-associated CD4+ TH1 cells into the inflamed intestine is likely to be beneficial in preventing a disease flare-up and even possibly in reducing the effect of acute disease. Thiazolidenedion...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.mib.0000160770.94199.9b

    authors: Schaefer KL,Denevich S,Ma C,Cooley SR,Nakajima A,Wada K,Schlezinger J,Sherr D,Saubermann LJ

    更新日期:2005-03-01 00:00:00